Features of the course of COPD as a comorbid condition of COVID-19.
DOI:
https://doi.org/10.52692/1857-0011.2025.3-83.13Keywords:
COVID-19, COPD, comorbidity, SARS-CoV-2Abstract
Introduction. COPD is a common comorbidity in patients with COVID-19, associated with an increased risk of severe forms and mortality.
Method. The study included patients with COPD and SARS-CoV-2 infection, divided into three groups: outpatient, outpatient consultation and hospitalized. Clinical parameters, respiratory function, Charlson score and vaccination status were analyzed.
Results. Hospitalized patients were older, had lower respiratory function and more comorbidities. The proportion of vaccinated patients was significantly lower in this group (33%) compared to outpatient patients (63%), suggesting the protective role of vaccination.
Conclusions. The evolution of patients with COPD and COVID-19 is determined by age, severity of lung disease and comorbidities. Vaccination reduces the risk of severe forms and hospitalization, highlighting the importance of prevention and an integrated approach to this vulnerable category.
References
Papi A., Bellettato C.M., Braccioni F., et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. American Journal of Respiratory and Critical Care Medicine. 2006; 173: 1114-1121.
Zhang X.Y., Huang H.J., Zhuang D.L., et al. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2. Infect Dis Poverty. 2020. 9(1). p.99.
Samuel R.M., Majd H., Richter M.N. et al. Androgen regulates SARS-CoV-2 receptor levels and is associated with severe COVID-19 symptoms in men. Cell Stem Cell. 2020; 27 (6): 876–889. e12. DOI: 10.1016/j.stem.2020.11.009.
Li M.Y., Li L., Zhang Y., Wang X.S. Expression of the SARSCoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect. Dis. Poverty. 2020; 9(1): 45.
Leung J.M., Yang C.X., Tam A. et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur. Respir. J. 2020; 55 (5): 2000688.
Lippi G., Henry B.M. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir. Med. 2020; 167: 105941.
Alqahtani J.S., Oyelade T., Aldhahir A.M. et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLoS One. 2020; 15 (5): e0233147.
Gerayeli F.V., Milne S., Cheung C., Li X., Yang C.W., et al. COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2021 Mar; 33: 100789. doi: 10.1016/j.eclinm.2021.100789. Epub 2021 Mar 18.
Celli B.R., Fabbri L.M., Aaron S.D. et al. An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: The Rome proposal. Am. J. Respir. Crit. Care Med. 2021; 204 (11): 1251–1258.
Halpin D.M. et al. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? The Lancet Respiratory Medicine, Vol. 8, Issue 5, 436 – 438.
“Федеральные клинические рекомендации МЗ РФ”, 2018. (In Russ.). https://spulmo.ru/upload/federal_klinicheskie_rekomendaciy_hobl.pdf
Rodriguez, R.R. Toward a consensus definition for COPD exacerbation. Chest 2000; 117: 398S–401S.
Alqahtani J. S., et al. COPD and COVID-19: a systematic review. Respir Med. 2021;176:106–110.
Halpin D. M., et al. Risk factors for severe COVID-19 in patients with COPD. Eur Respir J. 2020;56: 2002322.
Lippi G., Henry B. M. Chronic obstructive pulmonary disease and COVID-19 severity. Pulm Med. 2020;2020: 123–129.
Tenforde M. W., et al. Effectiveness of COVID-19 vaccines in patients with chronic respiratory diseases. N Engl J Med. 2021; 385:1332–1343.
Fiolet T., et al. Impact of vaccination on severe COVID-19 outcomes. Lancet Respir Med. 2021;9: 1055–1064.
Downloads
Published
License
Copyright (c) 2026 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
